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Rare diseases pose many challenges. A paucity of rando-
mised controlled trials for most conditions means that
best-practice care guidelines are often non-existent or
poorly developed. Where they exist, healthcare profes-
sionals may be unaware of them. Furthermore, evalua-
tion of guidelines is difficult, as traditional methods of
health-care research (such as hospital admissions and
mortality statistics with ICD codes) are not applicable to
rare diseases. The CARE-NMD project to improve care
for Duchenne muscular dystrophy (DMD) provides an
example of how Reference Networks may develop,
implement and monitor rare disease guidelines.
The development of the DMD care guidelines was
facilitated by the US Centres for Disease Control, and led
by patient organisations, translational research networks,
and health agencies. In the absence of overwhelming
clinical trial evidence, 84 international experts used the
RAND/UCLA Appropriateness Method (RAM) to gener-
ate consensus on the necessity and appropriateness of
clinical interventions and assessments. Yet despite the
guidelines, many DMD patients do not receive the treat-
ment they describe.
CARE-NMD has established a Reference Network of
care centres for DMD in Europe, to disseminate guide-
lines, evaluate current practice and identify reasons for
non-compliance, and assess guideline impact on quality of
life.
Dissemination, via professional and patient networks,
has addressed the problem of a lack of awareness of guide-
lines for this rare disease. Strategies have included presen-
tations at meetings, journal and website publications,
media interviews, and professional training courses tai-
lored to local needs in East European partner countries.
The ‘Family Guide’, a more accessible version of the care
guidelines, is now available in over 20 languages and has
been very well received.
To monitor implementation, the project has conducted
the largest ever cross-sectional study of DMD patients
and their families (n=1677, response rate 66%) across 7
European countries. This assessed – via process and out-
come indicators – whether the care they receive aligns
with the consensus guidelines, and reported quality of
life. In addition, a survey of healthcare professionals has
been distributed to care sites in these countries via
the Care and Trial Site Registry (CTSR), an online self-
registration platform for neuromuscular centres devel-
oped by the TREAT-NMD network of excellence. This
now includes information on patient cohort, care set-
tings, research activities and clinical trial capabilities of
more than 200 sites.
A Reference Network such as CARE-NMD enables
implementation, assessment and monitoring of care guide-
lines for rare diseases. The data it gathers will be crucial in
further developing and refining guidelines.
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